Abstract:BACKGROUND: A limitation of aspirin is that some patients, particularly those with diabetes, may not have an optimal antiplatelet effect.OBJECTIVES: The goal of this study was to determine if oral bioavailability mediates nonresponsiveness.METHODS: The rate and extent of serum thromboxane generation and aspirin pharmacokinetics were measured in 40 patients with diabetes in a randomized, single-blind, triple-crossover study. Patients were exposed to three 325-mg aspirin formulations: plain aspirin, PL2200 (a modified-release lipid-based aspirin), and a delayed-release enteric-coated (EC) aspirin. Onset of antiplatelet activity was determined by the rate and extent of inhibition of serum thromboxane B2 (TXB2) generation. Aspirin nonresponsiveness was defined as a level of residual serum TXB2 associated with elevated thrombotic risk (<99.0% inhibition or TXB2 >3.1 ng/ml) within 72 h after 3 daily aspirin doses.RESULTS: The rate of aspirin nonresponsiveness was 15.8%, 8.1%, and 52.8% for plain aspirin, PL2200, and EC aspirin, respectively (p < 0.001 for both comparisons vs. EC aspirin; p = 0.30 for comparison between plain aspirin and PL2200). Similarly, 56% of EC aspirin-treated subjects had serum TXB2 levels >3.1 ng/ml, compared with 18% and 11% of subjects after administration of plain aspirin and PL2200 (p < 0.0001). Compared with findings for plain aspirin and PL2200, this high rate of nonresponsiveness with EC aspirin was associated with lower exposure to acetylsalicylic acid (63% and 70% lower geometric mean maximum plasma concentration [Cmax] and 77% and 82% lower AUC0-t [area under the curve from time 0 to the last time measured]) and 66% and 72% lower maximum decrease of TXB2, with marked interindividual variability.CONCLUSIONS: A high proportion of patients treated with EC aspirin failed to achieve complete inhibition of TXB2 generation due to incomplete absorption. Reduced bioavailability may contribute to "aspirin resistance" in patients with diabetes. (Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients; NCT01515657).

Salicylic Acid Retention Impairs Aspirin Reactivity in Type 2 Diabetes.

Aspirin Inhibits Cancer Metastasis and Angiogenesis Via Targeting Heparanase

Effect of common single-nucleotide polymorphisms in acetylsalicylic acid metabolic pathway genes on platelet reactivity in patients with diabetes

Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study

[Aspirin Resistance in Patients Taking Small Dose of Aspirin].

Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus

Aspirin Resistance in Elderly Patients with Type 2 Diabetes and Analysis of Related Factors

Influence of aspirin on platelet activation during vascular endothelial injury induced by high blood glucose fluctuations

Lack of Benefits for Prevention of Cardiovascular Disease with Aspirin Therapy in Type 2 Diabetic Patients - A Longitudinal Observational Study

Salicylate-Based Anti-Inflammatory Drugs Inhibit the Early Lesion of Diabetic Retinopathy

Predictors of High On-Aspirin Platelet Reactivity in Elderly Patients with Coronary Artery Disease

Salicylates Promote Mitochondrial Biogenesis by Regulating the Expression of PGC-1α in Murine 3T3-L1 Pre-Adipocytes

Research Progress of Aspirin Resistance in Diabetic Statue

Aspirin Suppresses Hepatic Glucagon Signaling Through Decreasing Production of Thromboxane A2

Correlative Analysis of Aspirin Resistance with Gender and Age in Elderly Patients with Coronary Heart Dis-ease Accompanied by Type 2 Diabetes

Evaluating the Efficacy and Safety of Aspirin for Primary Cardiovascular Prevention in Asian Patients with Type 2 Diabetes: A Population-Based and Propensity Score-Matched Study

Effect of aspirin on platelet-rich plasma of diabetes mellitus with lower extremity atherosclerosis

Aspirin for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Meta-Analysis

Aspirin use in patients with diagnosed diabetes in the United States and China: Nationally representative analysis

Aspirin Resistance: Clinical Significance and Genetic Polymorphism